
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
WASHINGTON, D.C. 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **April 7, 2016**

Editas Medicine, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-37687
(Commission
File Number)

46-4097528
(IRS Employer
Identification No.)

300 Third Street, First Floor
Cambridge, Massachusetts
(Address of Principal Executive Offices)

02142
(Zip Code)

Registrant's telephone number, including area code: **(617) 401-9000**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 7, 2016, the board of directors (the “Board”) of Editas Medicine, Inc. (the “Company”) approved target amounts for bonuses for each of the Company’s named executive officers as follows, in each case set as a percentage of the named executive officer’s annual base salary:

Name	Title	Target Bonus as Percentage of Base Salary
Katrine S. Bosley	President and Chief Executive Officer	55%
Alexandra Glucksmann, Ph. D.	Chief Operating Officer	35%
Andrew A. F. Hack, M.D., Ph.D.	Chief Financial Officer	35%

In addition, on April 7, 2016, the Board also approved the award of discretionary cash bonuses of \$20,000 and \$30,000 to Dr. Glucksmann and Dr. Hack, respectively, for their contributions to the Company’s initial public offering.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EDITAS MEDICINE, INC.

Date: April 11, 2016

By: /s/ Katrine S. Bosley

Katrine S. Bosley

President and Chief Executive Officer
